Enzymatic strategies for (near) clinical development of antibody-drug conjugates

Sander S. van Berkel, Floris L. van Delft*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. At present, various (chemo)enzymatic approaches for site-specific and stable conjugation of toxic payloads are making their way to the clinic, thereby potentially providing ADCs with increased therapeutic window.

Original languageEnglish
Pages (from-to)3-10
JournalDrug Discovery Today: Technologies
Early online date11 Oct 2018
Publication statusPublished - Dec 2018

Fingerprint Dive into the research topics of 'Enzymatic strategies for (near) clinical development of antibody-drug conjugates'. Together they form a unique fingerprint.

  • Cite this